bpc-157 & tb-500 20mg blend (10 mg) + (20 mg) BPC-157 / TB-500 Peptide Blend

coli using a proprietary vector platform, specializes in Alzheimers and Parkinsons research targets such as beta-amyloid, tau, and alpha-synuclein, and has a published citation record in peer-reviewed neurodegeneration studies to back it up

Supplied as lyophilized powder

At the present time, payors have not published a local coverage policy that formally declares where, when, why, and how often they will pay for PBM, so providers must file claims to obtain a determination

In further embodiments, the invention encompasses a method of treating Parkinson and related neurological diseases by administering a therapeutically effective amount of one or more cations chosen from 1c, 1f, 1l, 1m, 2j, 2k, 2l, 2m, 2aa, 1c, 1f, 1l, 1m, 2j, 2k, 2l, 2m, and 2aa